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Purpose: To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits.
Methods: The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL 
bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. 
Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous.
Results: Maximum vitreous (406.25 µg/mL) and aqueous humor (5.83 µg/mL) concentrations 
of bevacizumab in the right eye were measured at day 1. Serum bevacizumab concentration 
peaked at day 8 (0.413 µg/mL) and declined to 0.032 µg/mL at 4 weeks. Half-life values in 
right vitreous, right aqueous humor, and serum were 6.61, 6.51, and 5.87 days,   respectively. 
  Concentration of bevacizumab in the vitreous of the noninjected eye peaked at day 8 
(0.335 ng/mL) and declined to 0.218 ng/mL at 4 weeks. In the aqueous humor of the nonin-
jected eye, maximum   concentration of bevacizumab was achieved at day 8 (1.6125 ng/mL) and 
declined (to 0.11 ng/mL) at 4 weeks.
Conclusion: The vitreous half-life of 1.25 mg/0.05 mL intravitreal bevacizumab was 6.61 days 
in this rabbit model. Maximum concentrations of bevacizumab were reached at day 1 in both 
vitreous and aqueous humor of the right eye and at day 8 in the serum. Very low concentrations 
of bevacizumab were measured in the fellow noninjected eye.
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Introduction
Bevacizumab (Avastin®, Genentech, South San Francisco, CA) is a humanized mono-
clonal antibody that inhibits human vascular endothelial growth factor (VEGF). VEGF 
is an endothelial cell-specific mitogen required for pathological angiogenesis observed 
in tumor growth and metastatic spread. Therefore, bevacizumab has been approved 
by the US Food and Drug Administration as an adjunct treatment for metastatic 
colorectal cancer.1 Bevacizumab is composed of 214 amino acids with a molecular 
mass of 149 kDa. Although some studies2 suggest that molecules exceeding 100 kDa 
cannot cross the retinal layers into the subretinal space, a number of other studies3,4 
have demonstrated that bevacizumab can efficiently diffuse through the retinal layers 
into the choroidal space where it can inhibit neovascularization. In this regard, intrav-
itreal injections of bevacizumab for off-label use have been shown to be beneficial in 
eyes with macular edema secondary to neovascular age-related macular degeneration 
(AMD),5,6 diabetic retinopathy,7–9 and central or branch retinal vein occlusion.10–12
The pharmacokinetics and distribution of bevacizumab after intravitreal injection 
of 1.25 mg/0.05 mL in rabbits have been studied.13,14 Interestingly, in these studies, 
very low concentrations of bevacizumab were detected in the fellow noninjected eye, Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
698
Sinapis et al
approaching the detection limit of the methods used. In our 
study, we aimed to measure the concentrations of bevaci-
zumab in both the injected and noninjected eye with more 
sensitive methods. It is important to know the exact pharma-
cokinetic profile of bevacizumab to optimize doses, assess 
its safety profile, and achieve the best therapeutic results not 
only in the injected but also in the noninjected eye.
Methods
Approval was obtained from the Ethics Committee of the 
National and Kapodistrian University of Athens and the 
Veterinary Address of Prefecture of Athens. The procedures 
adhered to the guidelines of the Association for Research in 
Vision and Ophthalmology for animal use in ophthalmic and 
vision research and were in accordance with the standards 
set down in the Guide for the Care and Use of Laboratory 
Animals. Twenty-four male New Zealand rabbits with a 
mean weight of 2.8975 kg (±0.2028 kg) were anesthetized 
with 20 mg/kg of intramuscular ketamine hydrochloride 
and 3 mg/kg of intramuscular xylazine hydrochloride. 
  Ophthalmic drops of 1% alcaine hydrochloride were placed 
on the conjunctiva of 20 right eyes and then povidone iodine 
5% was instilled in these eyes. These right eyes were injected 
intravitreally 2 mm behind the surgical limbus in the super-
otemporal quadrant with bevacizumab 1.25 mg/0.05 mL 
using a 30-gauge needle. The 20 left eyes received no intra-
vitreal injections and acted as controls. Eyes were monitored 
closely daily for any signs of adverse effects. Four rabbits 
received no intravitreal injections in the right eye and acted as 
controls to determine the background levels in the   detection 
of bevacizumab.
Four of the rabbits that received intravitreal injections of 
bevacizumab were sacrificed at each of the following days: 1, 
3, 8, 15, and 29. Rabbits were first anesthetized with 20 mg/kg 
of intramuscular ketamine hydrochloride and 3 mg/kg of 
intramuscular xylazine hydrochloride and then a sample of 
arterial blood was drawn from the central artery of their ears 
just before the euthanasia. Rabbits were then sacrificed with 
pentobarbital overdose (1.2 mL/kg). Serum was obtained by 
allowing the blood sample to clot at room temperature for 
1 hour followed by centrifugation. Serum was then frozen 
at −80°C until tested. The vitreous was taken with a 2.5 mL 
syringe while aqueous humor was withdrawn into an insulin 
syringe. All samples were immediately frozen at –80°C until 
tested. The four rabbits that acted as control animals were 
sacrificed and samples were obtained as mentioned above 
at day 0.
Bevacizumab assay
Bevacizumab concentrations were measured using enzyme-
linked immunosorbent assay (ELISA). Two ELISA meth-
ods were used, one of low sensitivity (LS ELISA, linear 
range: 5 ng/mL to 0.1 µg/mL, Figure 1A) and one of high 
sensitivity (HS ELISA, linear range: 10pg/mL to 5 ng/mL, 
Figure 1B). ELISA plates (Costar high binding) were 
coated with 100 µL/well of rec-hVEGF (R&D Systems, 
  Minneapolis, MN) at a concentration of 0.2 µg/mL in 
carbonate-  bicarbonate buffer (pH = 9.6). After washing 
with PBS (200 µL/well), the plates were blocked with 
200 µL/well of bovine albumin 2% in PBS (BB: blocking 
buffer).   Afterwards, the plates were washed and the samples 
were added (100 µL/well) in various dilutions ranging from 
1:10,000 (vitreous/right eye day1) to 1:1 (vitreous/left eye 
day 29) and incubated for 2 hours at room temperature (RT). 
The plates were then washed again and for i) LS ELISA: 
100 µL/well of anti-human Fab specific antibody conjugated 
to horse radish peroxidase (HRP) (Sigma-Aldrich, St Louis, 
MO) (1:1200 in BB) was added to the wells. After washing, 
100 µL of ABTS [2, 2′-azino-bis (3-ethylbenzthiazoline-
6-sulfonicacid)] substrate was added to the wells and the 
color development was measured at 405 nm, ii) HS ELISA: 
100 µL/well of anti-human Fab specific antibody conjugated 
to alkaline phosphatase (AP) (Jackson Immuno research, 
West Grove, PA) (1:1200 in BB) was added to the wells.
Subsequently, the plates were washed four times with PBS 
and the   Invitrogen’s ELISA amplification system was used to 
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Figure 1 Development of specific assays for the quantification of bevacizumab: 
A) low sensitivity eLiSA with linear range 5 to 100 ng/mL; B) high sensitivity eLiSA 
with linear range 10 to 5000 pg/mL.
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enhance the   detection of bevacizumab. Briefly, the plates were 
incubated with 50 µL/well of substrate (reduced NADPH) 
for 20 minutes followed by the addition of 50 µL/well of 
amplifier (alcohol dehydrogenase and   diaphorase). The color 
was quantified at 490 nm.
The detection limit of the designed assay was evalu-
ated using decreasing concentrations of bevacizumab. The 
detection limit was found to be 0.01 ng/mL (with the high-
  sensitivity assay). Intra- and inter-assay variations were 
determined using bevacizumab at concentrations 10, 50, 
and 100 ng/mL for the low-sensitivity assay and 0.1, 0.5, 
and 1.0 ng/mL for the high-sensitivity assay. Then, intra- and 
inter-assay variations were calculated using the formula:
% CV
SD
X
=
× 100
where CV = coefficient of variation, SD = standard deviation 
and X = mean.
Each dilution of bevacizumab was run eight times to 
calculate the coefficient of variation. Mean intra-assay and 
inter-assay CV were found to be 3.96% and 6.75% for the 
low-sensitivity assay and 4.4% and 8.19% for the high-
sensitivity assay, respectively.
eLiSA assay for detection  
of anti-bevacizumab antibodies  
(rabbit anti-idiotypic antibodies)
We additionally performed an ELISA assay for detection 
of anti-bevacizumab antibodies in order to quantify their 
effect on bevacizumab concentration. According to this 
method, ELISA plates (Costar high binding) were coated 
with 100 µL/well of bevacizumab at a concentration of 
0.4 µg/mL in carbonate-bicarbonate buffer (pH = 9.6).
After washing with PBS (200 µL/well), the plates were 
blocked with 200 µL/well of bovine albumin 2% in PBS 
(BB:     blocking buffer).
Subsequently,  the  serum  samples  were  added 
(100 µL/well) in 1:5 dilution and incubated for 2 hours at RT. 
The plates were then washed again and 100 µL/well of anti-
rabbit Fc specific antibody conjugated to AP (1:1200 in BB) 
was added to the wells. Afterwards, the plates were washed 
with PBS (200 µL/well) and the Invitrogen ELISA amplifica-
tion system was used according to the procedure described 
above. Finally, the color was quantified at 490 nm.
Pharmacokinetic methods
Bevacizumab vitreous humor, aqueous humor, and   serum 
concentration–time data were each fit by standard noncom-
partmental analysis to determine half-life (t1/2), area under the 
curve (AUC0→∞) and bevacizumab vitreous clearance using 
WinNonlin Pro (v2.1; Pharsight, Mountain View, CA). The 
terminal elimination rate constant was determined by least-
squares regression of the ln (serum concentration)–time data 
for the last four time points.
Results
Data were obtained from the 48 eyes of 24 rabbits. There were 
no signs of ocular inflammation or other adverse events. The 
change in concentration over time for bevacizumab in the 
vitreous and aqueous humor of injected eye and in serum after 
intravitreal injection is illustrated in Figure 2. A peak concen-
tration of 406.25 µg/mL was achieved in the vitreous 1 day 
after intravitreal injection of 1.25 mg/0.05 mL bevacizumab. 
Half-life of bevacizumab in the right vitreous was 6.61 days 
(Table 1). A concentration of 5.17 µg/mL was maintained in 
the vitreous 29 days after injection.   Bevacizumab concentra-
tions in the aqueous humor of the injected eye reached a peak 
concentration of 5.835 µg/mL 1 day after drug administration 
as well. A concentration of 0.225 µg/mL was maintained in 
aqueous humor 29 days after injection. In serum, a maximum 
concentration of 0.413 µg/mL was achieved 8 days after drug 
injection and the concentration fell to 0.032 µg/mL 29 days 
Table 1 Analysis of distribution of bevacizumab in the aqueous, vitreous, and serum after intravitreal injection of 1.25 mg/0.05 mL 
bevacizumab in the right eye
Compartment t1/2 
(days)
Tmax 
(days)
Cmax 
(ng/mL)
% of vitreous 
Cmax
AUC0→∞ 
(μg/mL * day)
Exposure to 
bevacizumab as a % 
of vitreous exposure
Vitreous (r) 6.61 1 406250 – 1455.1 –
Aqueous (r) 6.51 1 5835 1.44 44.8 3.08
Serum 5.87 8 413 0.10 5.3 0.36
Aqueous (L) 5.56 8 1.61 0.0004 0.018 0.001
Vitreous (L) – 8 0.34 0.00008 0.017 0.001
Abbreviations: r, right eye; L, left eye; Tmax, day when concentration of bevacizumab peaked; Cmax, maximum concentration; AUC, area under the curve.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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after drug administration. Half-life of bevacizumab in the 
right aqueous humor and serum were 6.51 and 5.87 days, 
respectively (Table 1).
Very low concentrations of the drug were detected in 
the fellow noninjected eye. The levels of bevacizumab in 
the aqueous humor of the noninjected eye peaked at 8 days 
after intravitreal injection with a concentration of 1.61 ng/mL 
and declined to 0.11 ng/mL at 29 days. For the vitreous 
of the noninjected eye, the levels of bevacizumab ranged 
from 0.245 ng/mL at 1 day after injection to a maximum of 
0.335 ng/mL at 8 days and then declined to 0.218 ng/mL 
at 29 days. Figure 3 shows the change in concentration of 
bevacizumab in the aqueous and vitreous humor of the   fellow 
noninjected eye.
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Figure 2 Bevacizumab concentration in the vitreous, aqueous humor, and serum after intravitreal injection of 1.25 mg/0.05 mL of bevacizumab in rabbits. Samples were taken 
from the aqueous humor and vitreous of the injected right eye. Values at day 0 indicate background levels of bevacizumab detection in control animals.
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Figure 3 Bevacizumab concentration in the vitreous and the aqueous humor of the noninjected left eye after intravitreal injection of 1.25 mg/0.05 mL bevacizumab into the 
fellow eye. Values at day 0 indicate background levels of bevacizumab detection in control animals.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The results of high sensitivity ELISA assay for the detec-
tion of anti-bevacizumab antibodies are illustrated in Figure 4. 
There was a 30% increase of anti-bevacizumab antibodies 
at day 1, 60% at day 3, and 70% at day 8. Subsequently, the 
anti-bevacizumab activity of antibodies gradually decreased 
(to 120% of the initial levels at day 29), following the elimi-
nation of bevacizumab from blood circulation. Taking into 
account the absolute optical density values of the measure-
ments of the high sensitivity ELISA, compared with the high 
sensitivity assay for bevacizumab, we can conclude that the 
concentration of anti-bevacizumab antibodies in serum is at 
least 200-fold lower than the bevacizumab concentration. 
Therefore, anti-bevacizumab antibodies cannot have an 
important effect on bevacizumab concentration because of 
their low concentration.
The cytotoxicity of the drug is currently under investi-
gation in our laboratory. Our preliminary results show no 
important histological changes in all the anatomical parts 
that were examined by light microscopy (Figure 5). In both 
injected and noninjected eyes, no signs of necrosis or degen-
eration of the retina were noticed and the retinal thickness 
was unchanged. Only some specimens of the right injected 
eyes revealed chronic inflammatory infiltrations (indicated 
by arrows in Figure 5) consisting of lymphocytes, plasma 
cells, and rarely eosinophils. The left noninjected eyes had 
no histological changes as seen by light microscopy.
Discussion
In our study, we aimed to describe the pharmacokinetics of 
1.25 mg/0.05 mL intravitreal bevacizumab in rabbits. This 
is the dose that is currently being used in human eyes and is 
widely described in the literature.4,7–9,11,13–16 The assay we used 
measures free bevacizumab and does not detect complexes of 
bevacizumab with bound VEGF. Assays which detect only 
the free drug are used widely in pharmacologic research and 
results are usually considered good representations of total 
drug concentration. However, an underestimation of the total 
bevacizumab concentration by our results cannot be excluded 
because of partial denaturation or proteolytic degradation 
of bevacizumab which may take place in samples.
Studies of pharmacokinetics of intravitreal bevacizumab 
in rabbits have already been published.13,14 Nevertheless, it is 
very important to make measurements as accurate as possible 
in order to know the exact pharmacokinetics of bevacizumab 
and optimize drug dosing and therapeutic results in both 
injected and noninjected eyes.
Our results show that the maximum concentration of 
bevacizumab in the right vitreous is measured at day 1 after 
injection (406 µg/mL) and then declines, but it remains at 
high levels 29 days after injection (5 µg/mL). Maximum 
concentration of bevacizumab in right aqueous was mea-
sured at day 1 as well and not at day 3 as in the Bakri et al 
study, in which it was much lower (5.8 µg/mL instead of 
37.7 µg/mL).13 Maximum concentration of bevacizumab 
in serum is measured 8 days after intravitreal injection 
due to its gradual distribution from the right eye to serum 
  (vitreousR→­ aqueousR→serum).13 On the same day (day 8), 
we measured the maximum concentration of bevacizumab 
in the left aqueous because bevacizumab is very easily and 
quickly distributed from serum to left aqueous (serum →­
aqueousL).13 The concentration of bevacizumab in the left 
vitreous reached a peak concentration at day 8 and then 
gradually declined, not constantly raised as in the Bakri et al 
study.13 The reduction of bevacizumab concentration in the 
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Figure 4 Quantification of anti-bevacizumab antibodies in serum of rabbits at day 0 (before intravitreal injection of bevacizumab) and at days 1, 3, 8, 15, and 29 after injection.
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left vitreous after day 8 is caused by the reduction of drug 
concentration in serum and left aqueous.
In our rabbit model we used high sensitivity ELISA (lin-
ear range 10 pg/mL to 5 ng/mL) in order to measure drug 
concentrations in the left eye and low sensitivity ELISA 
(with linear range between 5–100 ng/mL) to measure drug 
concentrations in the right eye. In this regard, we avoided 
dilutions in the order of 1 million-fold, required for the mea-
surement of bevacizumab with the HS assay in the right eye, 
which would inevitably be accompanied by a 1 million-fold 
increase of the measurement errors. On the other hand, the 
HS assay (with detection limit at 5 pg/mL) was necessary to 
assure the accurate detection of the very low concentrations 
of bevacizumab in the noninjected eye. This is the reason we 
measured considerably lower concentrations in the fellow eye 
compared with those of the Bakri et al study.13
We also measured considerably lower concentrations in 
the aqueous and vitreous of the fellow noninjected eye and 
higher concentrations in the aqueous and vitreous of the 
injected eye compared with the values in the Nomoto et al 
study.14 In addition, we measured lower concentrations in 
serum and we found that the maximum concentration of beva-
cizumab in serum was achieved at day 8 and not at day 14, 
as in the Nomoto et al study.14 In our assay, hVEGF was 
used in order to capture and quantify ‘active’ bevacizumab 
molecules with a detection limit of 0.01 ng/mL. Nomoto 
et al used anti-rabbit IgG (Heavy +­Light chains) to capture 
antibodies with a detection limit of 0.1 ng/mL. In that case, 
both native and denatured bevacizumab molecules as well 
as their fragments were quantified with questionable ability 
to recognize hVEGF. Moreover, we obtained samples more 
frequently during the first month (days 1, 3, 8, 15, and 29) 
and thus we demonstrated a more detailed pharmacokinetic 
profile of bevacizumab during the first month compared 
with the Nomoto et al study. Finally, our results depict 
the variations between animals and the development of 
  anti-bevacizumab antibodies.
The variability of results between animals was very low 
for the right eye but considerably higher for the left eye (see 
error bars in Figures 2 and 3). The maximum variability 
was observed at day 15 for one of the rabbits (rabbit with 
identification number R13), which had considerably higher 
concentration of bevacizumab in the left eye than the other 
three rabbits on the same day (0.63 ng/mL in the left vitre-
ous and 0.8 ng/mL in the left aqueous, while the other three 
rabbits had an average of 0.19 ng/mL and 0.25 ng/mL in 
the left vitreous and left aqueous on the same day, respec-
tively). These very high concentrations of bevacizumab in 
rabbit R13 may have been caused by a higher distribution 
rate of drug from the right vitreous to serum and then to 
the left aqueous and vitreous, most probably due to inflam-
mation, infection, or traumatic damage of vessels in the 
injection area.
As we have already mentioned, very low concentrations 
of bevacizumab were detected in the fellow noninjected eye. 
It is very important to know if these concentrations are able 
to achieve therapeutic results in this eye. Wang et al17 found 
that bevacizumab displayed a dose-dependent inhibition in an 
in vitro endothelial cell proliferation assay, with an estimated 
median inhibition concentration of 22 ng/mL. In our study, 
the maximum concentration of bevacizumab in the vitreous of 
the noninjected eye was much lower (0.335 ng/mL). Our find-
ings suggest that intravitreal injection of 1.25 mg/0.05 mL 
bevacizumab in one eye cannot achieve therapeutic concen-
trations in the fellow noninjected eye, even though Avery 
et al9 reported that some patients with bilateral proliferative 
diabetic retinopathy had regression of neovascularization in 
both eyes when injected with intravitreal bevacizumab in 
only one eye.
Rabbits have been widely used in order to study intra-
vitreal pharmacokinetics of drugs.18–20 There are some dif-
ferences between humans and rabbits which may affect the 
study of the drug’s pharmacokinetics. The most important 
are that humans have a larger vitreous cavity (4.5 mL instead 
of 1.5 mL in rabbits), a larger serum compartment, and a 
more vascular retina. Krohne et al,21 in a study of pharma-
cokinetics of intravitreal bevacizumab in humans, found that 
after a single intravitreal injection of 1.5 mg bevacizumab, 
AB
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Figure 5 Light micrographs of 4µm thick sections stained with hematoxylin-eosin 
revealed chronic inflammatory infiltrations (A) especially in the nerve fiber layer of 
the retina around the optic disc (B) and in iris (C) in a few specimens. no other 
histological differences were evident between injected and noninjected eyes in the 
rest of the specimens (D).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the concentration of the drug in the aqueous humor peaked 
on the first day after injection (33.3 µg/mL) and dropped to 
less than 5 µg/mL at day 28. These concentrations are much 
higher than those in our study (5.8 and 0.2 µg/mL, respec-
tively). Zhu et al15 measured vitreous levels of bevacizumab 
after intravitreal injection of 1.25 mg of bevacizumab and 
found that maximum concentration was achieved at day 2 
after injection instead of day 1 in our study. Furthermore, 
the maximum concentration of bevacizumab was 165 µg/
mL instead of 406 µg/mL in our study.
In our study, we used nonvitrectomized eyes. In vit-
rectomized eyes, clearance of the drug may be markedly 
increased. After intravitreal injection of triamcinolone 
acetonide in rabbits, the half-life in the aqueous humor 
was reported to be 2.89 days in nonvitrectomized eyes and 
1.57 days in vitrectomized eyes.22 In humans, Beer et al23 
reported that the half-life of the same drug in the aqueous 
humor after intravitreal injection of triamcinolone acetonide 
was 18.6 days in nonvitrectomized eyes compared with 
3.2 days in vitrectomized eyes. Similar effects should be 
expected for bevacizumab in vitrectomized eyes and may 
result in a lack of clinical effect of bevacizumab, as reported 
by Yanyali et al16 in vitrectomized human eyes with diabetic 
macular edema.
Besides bevacizumab, its derivative drug ranibizumab 
(Lucentis®; Genentech; South San Francisco, CA) is now 
widely used as intravitreal anti-VEGF therapy for neovas-
cular AMD. Bevacizumab has a larger molecular weight 
(149 kDa)24 than ranibizumab (48 kDa)25 and its penetration 
into the retina may be slower than ranibizumab’s. Its clear-
ance from the vitreous may be slower as well, resulting in 
a longer half-life in the human eye, thus requiring less fre-
quent application. In rabbits, Bakri et al reported a vitreous 
half-life of 2.88 days after intravitreal injection of 0.5 mg 
ranibizumab,26 which indeed is shorter than the half-life 
reported for bevacizumab (4.32 days) in the same animal 
model.13 In monkeys, the vitreous elimination half-life 
of ranibizumab was determined by Gaudreault et al to be 
2.6 days after bilateral intravitreal injection of 0.5 mg of the 
drug.27 With the increasing use of intravitreal injections of 
anti-VEGF substances for various ocular diseases, accurate 
information on their pharmacokinetics is very important and 
will help to optimize reinjection intervals and achieve the 
maximum therapeutic results.
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